<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Moderna Inc (NASDAQ: MRNA) said that the FDA would require additional time to complete its assessment of its COVID-19 vaccine for use in adolescents aged 12 to 17 years. The FDA may not complete the Moderna’s shot review before January 2022, dealing with a potential setback to the timing of an emergency use authorization (EUA) for that age group.
...read full article on Benzinga
